Skip to main content
. Author manuscript; available in PMC: 2023 Jul 27.
Published in final edited form as: Cell. 2023 Jul 5;186(15):3148–3165.e20. doi: 10.1016/j.cell.2023.06.002

Figure. 4. Vaccine boosting induces cell-intrinsic enhancements in CAR T-cell function that include metabolic reprogramming.

Figure. 4.

(A) Tumor growth (left) and overall survival (right) of tumor-bearing mice (n=8) after receiving vaccine-boosted or non-boosted CAR T cells. Created with BioRender.com.

(B-C) Tumor-bearing mice received WT CAR T ± vax treatment, and CAR T-cells were isolated from spleens and tumors for RNA-seq.

(B) Volcano plot showing differential gene expression in splenic CAR T-cells.

(C) GSEA showing enriched pathways in intratumoral CAR T-cells.

(D-E) Intracellular PGC-1α expression (D) and mitochondrial mass (E) in intratumoral CAR T cells from mice (n=5) 7 days post treatment with WT CAR T ± vax.

(F) IFN-γ ELISPOT. Tumor-bearing mice (n=5) treated with WT CAR T ± vax or PGC-1α−/− CAR T-vax.

All mice bear EGFRvIII+CT-2A tumors. Error bars are mean ± 95% CI, **, p<0.01; *, p<0.05 by Student’s t-test for D-E, and one-way ANOVA with Tukey’s post-test for F.